Take a look behind the scenes of a recent Future Microbiology review as we ask the authors about quorum quenching and using nanoparticles as antibiotics.
Browsing: Basic > Drug Development
New research has developed a nanoparticle formulation that can knock down a key chlamydia binding protein and simultaneously induce autophagy – showing promise against this infection.
Some of the challenges with mass ivermectin administration could be addressed with new drugs or drug combinations with higher effect for the parasite – leading us to ask, what new treatments are currently in the clinical pipeline?
Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
The UK government has published a 20-year vision and a 5-year national action plan for how the UK will contribute to controlling and containing antimicrobial resistance by 2040.
Take a look at this month’s industry headlines including a new partnership for antibiotic development, approval for HIV drugs and authorization for a cytomegalovirus test.
A bacteriophage, VP882, has been identified to use bacterial quorum-sensing as a method to control the lysis-lysogeny decision. This is the first time a virus has been shown to detect a bacterial molecule.
Take a look behind the scenes of a recent Future Microbiology paper as we ask the authors about the challenges in treating respiratory tract infections and how nanomedicines could help.
New research has suggested that the spread of prions to the brain does not occur via the blood–brain barrier, implicating other mechanisms.
Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.